Vanguard Group
NEXI

Vanguard Group’s NexImmune, Inc. Common Stock NEXI Stock Holding History

Vanguard Group’s Portfolio NEXI Stock Details NEXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,010
Closed -$33.1K – 4445
2024
Q2 		$33.1K Hold
12,010
– – ﹤0.01% 4320
2024
Q1 		$67.4K Buy
+12,010
New +$92.5K ﹤0.01% 4280
2023
Q4 		– Sell
-3,893
Closed -$20.4K – 4520
2023
Q3 		$20.4K Hold
3,893
– – ﹤0.01% 4497
2023
Q2 		$27.4K Sell
3,893
-15,066
-79% -$130K ﹤0.01% 4503
2023
Q1 		$180K Hold
18,959
– – ﹤0.01% 4335
2022
Q4 		$115K Hold
18,959
– – ﹤0.01% 4376
2022
Q3 		$263K Buy
18,959
+1,082
+6% +$31.7K ﹤0.01% 4377
2022
Q2 		$720K Buy
17,877
+1,467
+9% +$90.8K ﹤0.01% 4188
2022
Q1 		$1.73M Sell
16,410
-10,889
-40% -$800K ﹤0.01% 4015
2021
Q4 		$3.15M Buy
27,299
+105
+0.4% +$25.2K ﹤0.01% 3857
2021
Q3 		$10.3M Buy
27,194
+12,743
+88% +$4.27M ﹤0.01% 3223
2021
Q2 		$5.9M Buy
14,451
+6,201
+75% +$2.86M ﹤0.01% 3509
2021
Q1 		$3.94M Buy
+8,250
New +$4.49M ﹤0.01% 3652

Other funds holding NEXI

RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Vanguard Group's NEXI Position: Q3 2024 in Review

Vanguard Group sold out of NexImmune, Inc. Common Stock (NEXI) in Q3 2024, closing a stake of 12,010 shares — an estimated $33.1K sold.

Vanguard Group first reported a position in NEXI in Q1 2021 and held it in 13 quarters. The position peaked at $10.3M in Q3 2021. 1 fund tracked by Wall St. Rank holds NEXI as of Q3 2024.

  • Vanguard Group reported no remaining NexImmune, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Vanguard Group sold 12,010 NexImmune, Inc. Common Stock shares in Q3 2024, an estimated $33.1K.
  • Vanguard Group first reported a position in NexImmune, Inc. Common Stock in Q1 2021 and held it in 13 quarters.
  • Vanguard Group's NexImmune, Inc. Common Stock position peaked at $10.3M in Q3 2021.
  • 1 fund tracked by Wall St. Rank held NexImmune, Inc. Common Stock as of Q3 2024.

Based on Vanguard Group's 13F filing for Q3 2024, filed 13 Nov 2024.